NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
1 trialsLugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Brentuximab Vedotin × 90 days × Clear all